+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women



Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women



Annals of the Rheumatic Diseases 62(10): 969-975



Objective: To investigate the efficacy, safety, and dose response of three doses of ibandronate, given intermittently by intravenous (IV) injection every three months, in preventing postmenopausal osteoporosis. Patients and methods: 629 postmenopausal women, categorised according to time since menopause and baseline lumbar spine (L1-4) bone mineral density (BMD), were enrolled into a multicentre, double blind, placebo controlled trial. They were randomly allocated to receive IV ibandronate 0.5 mg, 1 mg or 2 mg, or placebo every three months. All women received daily calcium supplementation. Results: One year's treatment with intermittent IV ibandronate injections produced a dose dependent gain in mean (SD) lumbar spine BMD from baseline of 2.5 (2.5)%, 1.8 (2.6)%, and 1.0 (2.8)% in the groups receiving 2 mg, 1 mg, and 0.5 mg ibandronate, respectively, compared with a loss of BMD of 0.4 (2.4)% in the women in the placebo group; p=0.0001 for each ibandronate dose v placebo. Highest BMD gains occurred in women with osteopenia receiving 2 mg ibandronate. Similarly, at the hip, all three doses of ibandronate produced significantly better gains in BMD than placebo (p<0.05), with the greatest gains in the women with osteopenia receiving the 2 mg dose. Ibandronate concomitantly and dose dependently suppressed markers of bone turnover in comparison with placebo, and injections were well tolerated. Conclusion: IV ibandronate injections, given every three months, may be an effective alternative to oral bisphosphonates and hormonal therapy in the prevention of bone loss in postmenopausal women.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012233387

Download citation: RISBibTeXText

PMID: 12972476

DOI: 10.1136/ard.62.10.969


Related references

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone 46(3): 660-665, 2010

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis and Rheumatism 54(6): 1838-1846, 2006

Intravenous injections of ibandronate (IB) in the treatment of postmenopausal osteoporosis. Osteoporosis International 6(1 Suppl.): 94-94, 1996

Tri-monthly intravenous injections of ibandronate for treatment of postmenopausal osteoporosis. Journal of Bone & Mineral Research 16(Suppl 1): S406, 2001

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. American Journal of Medicine 103(4): 298-307, 1997

Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension. 2007

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. Journal of Bone and Mineral Metabolism 28(3): 299-305, 2010

Oral weekly ibandronate prevents bone loss in postmenopausal women. Journal of Internal Medicine 254(2): 159-167, 2003

Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis. Journal of Bone & Mineral Research 17(Suppl 1): S157, 2002

Intermittent intravenous ibandronate injections are more effective than daily oral ibandronate for improving bone density at the hip: DIVA 2-year analysis. 2006

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. Journal of Bone and Mineral Research 19(1): 11-18, 2004

Ibandronate injections in postmenopausal women with osteoporosis. Current Rheumatology Reports 9(1): 47; Discussion 48-9, 2007

Treatment of postmenopausal women with medroxyprogesterone to prevent bone loss reduced gonadotropins osteocalcin calcitonin and parathyroid hormone. Clinical Research 37(2): 459A, 1989

Efficacy of Intravenous Ibandronate Injections in Postmenopausal Osteoporosis: DIVA 2-Year Findings. Journal of Clinical Densitometry 9(2): 247-248, 2006

Suppression of bone resorption was restored within two months after quarterly intravenous bolus infusion of ibandronate in Japanese osteopenic women without vitamin D and calcium supplementation. Journal of Bone & Mineral Research 17(Suppl 1): S369, 2002